![]() ![]() Stakeholders were consulted in the following ways: The aim was to collect views and opinions on the implementation of the blood, tissues and cells legislation, to gather factual information on what works well and where there is still room for improvement and to gather data and knowledge about the impact of the legislation. Stakeholder consultation was one of the key sources of evidence that was used to support this evaluation. The External Study, together with an Executive Summary was published together with the BTC evaluation. They conducted an extensive literature review and consulted stakeholders through interviews and focus groups. ICF had supported several evaluations of EU legal frameworks in the field of health and food safety and they sub-contracted experts in blood, tissues and cells to support their work on this study. was selected to perform the study and their work commenced in 2017. Where information gaps remained, the contractor explored additional sources of information.Ī request for services was sent to the 4 eligible contractors who had signed a framework contract with DG SANTE on evaluation and impact assessment in public health. This study was based on Commission documents and reports, the relevant published literature, documents developed by other bodies (such as the European Parliament, the Council of Europe or the World Health Organisation) and the results of the public and targeted consultation. External StudyĪn external contractor was commissioned to prepare a study to support the evaluation. To view the feedback received, please click here (Zip file). Stakeholders were invited to submit comments on the Roadmap up to 15 February 2017. This Roadmap was a first step in the evaluation process and outlined the purpose, content and scope of the evaluation. The Commission published a Roadmap on the evaluation of the EU blood and tissues and cells legislation. A summary report of the event is published. The conference allowed stakeholders to discuss the findings and express their views on the way forward. The results of the evaluation were disseminated at a Conference in Brussels on 28 October 2019. Reflections on follow-up actions are now underway in the Commission. The evaluation consisted of several steps, starting with the publication of a Roadmap and including a study by an external contractor and extensive consultation of stakeholders. The evaluation was conducted in line with the Commission’s Better Regulation Guidelines and aimed to assess whether the legislation achieved its original objectives and whether it is still fit for purpose. This was the first evaluation of the legislation since the adoption of the basic Acts in 2002 ( blood) and 2004 ( tissues and cells). An Executive Summary in English, French and German is also available. On 11 October 2019, the Commission published its Evaluation on the EU blood, tissues and cells legislation.
0 Comments
Leave a Reply. |
Details
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |